Primary Objective~1. To evaluate tumour ablation in tumours and/or tumour segments following one or more treatments with tigilanol tiglate.~Secondary Objective~To assess the safety and tolerability of intratumoural injections with tigilanol tiglate; and~To evaluate systemic exposure through pharmacokinetic (PK) assessment after a single intratumoural injection of tigilanol tiglate.~Exploratory Objectives~To evaluate the microenvironment of injected tumours;~To evaluate the degree of immune response elicited with intratumoural tigilanol tiglate;~To evaluate local recurrence rate.
A Phase IIa open label study evaluating the preliminary efficacy of intratumoural tigilanol tiglate in advanced and/or metastatic soft tissue sarcoma of the extremities and body wall.